Mefuparib (hydrochloride)

Mefuparib hydrochloride (MPH) is an orally active, substrate-competitive and selective PARP1/2 inhibitor with IC50s of 3.2 nM and 1.9 nM, respectively. Mefuparib hydrochloride induces apoptosis and possesses prominent anticancer activity in vitro and in vivo[1][2].

Product Specifications

CAS Number

[1449746-00-2]

Product Name Alternative

MPH

UNSPSC

12352005

Target

Apoptosis; PARP

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/mefuparib-hydrochloride.html

Purity

98.62

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

O=C(C1=C(OC(C2=CC=C(CNC)C=C2)=C3)C3=CC(F)=C1)N.[H]Cl

Molecular Formula

C17H16ClFN2O2

Molecular Weight

334.77

References & Citations

[1]He JX, et al. Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution. Oncotarget. 2017 Jan 17;8 (3) :4156-4168.|[2]Nie D, et al. Cancer-Cell-Membrane-Coated Nanoparticles with a Yolk-Shell Structure Augment Cancer Chemotherapy. Nano Lett. 2020 Feb 12;20 (2) :936-946.